PPA
RXRX icon

Parametric Portfolio Associates’s Recursion Pharmaceuticals RXRX Stock Holding History

Parametric Portfolio Associates’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$168K Sell
23,424
-14,867
-39% -$158K ﹤0.01% 3484
2021
Q4 		$656K Buy
+38,291
New +$720K ﹤0.01% 2953

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $17.2M AUM 22.94% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parametric Portfolio Associates's RXRX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Recursion Pharmaceuticals (RXRX) stake by 39% in Q1 2022, selling an estimated $158K and leaving 23,424 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #3484.

Parametric Portfolio Associates first reported a position in RXRX in Q4 2021 and has held it in 2 quarters since. The position peaked at $656K in Q4 2021. 128 funds tracked by Wall St. Rank hold RXRX as of Q1 2022.

  • Parametric Portfolio Associates held 23,424 shares of Recursion Pharmaceuticals worth $168K as of Q1 2022.
  • Parametric Portfolio Associates sold 14,867 Recursion Pharmaceuticals shares in Q1 2022, an estimated $158K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3484 holding.
  • Parametric Portfolio Associates first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Parametric Portfolio Associates's Recursion Pharmaceuticals position peaked at $656K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.